Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212454759> ?p ?o ?g. }
- W3212454759 endingPage "1252" @default.
- W3212454759 startingPage "1252" @default.
- W3212454759 abstract "Background and Objectives: Lung cancer is the second most common cancer in the world. Non-small-cell lung carcinoma (NSCLC) makes up 85% of all lung cancer cases and the majority of patients are diagnosed when the cancer is advanced. Over the years, many anticancer drugs have been designed and introduced into the market to treat patients with advanced NSCLC. This review aims to discuss the comparative therapeutic benefits of conventional chemotherapeutics and other drugs available for treating advanced NSCLC. Materials and Methods: A literature search for first-line treatment of advanced NSCLC was carried out on PubMed and Google Scholar. Objective response rate (ORR) and overall survival were chosen as target endpoints. Results: Monotherapy showed lower treatment endpoints compared to combination therapy. Different combinations of platinum-based doublets demonstrated similar efficacies in treating NSCLC. However, pemetrexed-platinum doublets showed significantly better treatment endpoint in patients with non-squamous NSCLC. Most studies showing the best complete response rate (CRR) utilized epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), while most studies producing the best overall survival included programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors in their treatment regimens. Conclusions: The findings of this review indicate that targeted therapy using specific inhibitors is now the most promising first-line anticancer treatment available in the market. However, chemotherapy is still effective in treating advanced NSCLC and is viable as a first-line treatment." @default.
- W3212454759 created "2021-11-22" @default.
- W3212454759 creator A5054845803 @default.
- W3212454759 creator A5090107841 @default.
- W3212454759 date "2021-11-16" @default.
- W3212454759 modified "2023-09-26" @default.
- W3212454759 title "Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients" @default.
- W3212454759 cites W1837121308 @default.
- W3212454759 cites W1837502540 @default.
- W3212454759 cites W1848316250 @default.
- W3212454759 cites W1910129380 @default.
- W3212454759 cites W1935885922 @default.
- W3212454759 cites W1964370859 @default.
- W3212454759 cites W1968154447 @default.
- W3212454759 cites W1972728281 @default.
- W3212454759 cites W1985887686 @default.
- W3212454759 cites W1988338874 @default.
- W3212454759 cites W1996285570 @default.
- W3212454759 cites W2004484157 @default.
- W3212454759 cites W2013113867 @default.
- W3212454759 cites W2019607817 @default.
- W3212454759 cites W2025614206 @default.
- W3212454759 cites W2030675939 @default.
- W3212454759 cites W2035333264 @default.
- W3212454759 cites W2037139573 @default.
- W3212454759 cites W2046261571 @default.
- W3212454759 cites W2046639680 @default.
- W3212454759 cites W2070184017 @default.
- W3212454759 cites W2070611680 @default.
- W3212454759 cites W2071069178 @default.
- W3212454759 cites W2074190059 @default.
- W3212454759 cites W2076315677 @default.
- W3212454759 cites W2076668534 @default.
- W3212454759 cites W2089618673 @default.
- W3212454759 cites W2096198395 @default.
- W3212454759 cites W2097268198 @default.
- W3212454759 cites W2099530756 @default.
- W3212454759 cites W2099725888 @default.
- W3212454759 cites W2102995554 @default.
- W3212454759 cites W2106664438 @default.
- W3212454759 cites W2111179508 @default.
- W3212454759 cites W2111662961 @default.
- W3212454759 cites W2113003672 @default.
- W3212454759 cites W2115330744 @default.
- W3212454759 cites W2116996913 @default.
- W3212454759 cites W2118396147 @default.
- W3212454759 cites W2119321434 @default.
- W3212454759 cites W2121834332 @default.
- W3212454759 cites W2127101185 @default.
- W3212454759 cites W2127405377 @default.
- W3212454759 cites W2128215600 @default.
- W3212454759 cites W2129360604 @default.
- W3212454759 cites W2129447971 @default.
- W3212454759 cites W2129793485 @default.
- W3212454759 cites W2132157071 @default.
- W3212454759 cites W2132870547 @default.
- W3212454759 cites W2135140316 @default.
- W3212454759 cites W2136503777 @default.
- W3212454759 cites W2144660856 @default.
- W3212454759 cites W2145835533 @default.
- W3212454759 cites W2147036796 @default.
- W3212454759 cites W2148367564 @default.
- W3212454759 cites W2150358925 @default.
- W3212454759 cites W2151090489 @default.
- W3212454759 cites W2151518427 @default.
- W3212454759 cites W2154581953 @default.
- W3212454759 cites W2154948351 @default.
- W3212454759 cites W2156728903 @default.
- W3212454759 cites W2162724777 @default.
- W3212454759 cites W2164310161 @default.
- W3212454759 cites W2166399931 @default.
- W3212454759 cites W2168708405 @default.
- W3212454759 cites W2171139285 @default.
- W3212454759 cites W2256453366 @default.
- W3212454759 cites W2274832923 @default.
- W3212454759 cites W2335671095 @default.
- W3212454759 cites W2527905628 @default.
- W3212454759 cites W2572035171 @default.
- W3212454759 cites W2604580902 @default.
- W3212454759 cites W2607954371 @default.
- W3212454759 cites W2624310346 @default.
- W3212454759 cites W2626223149 @default.
- W3212454759 cites W2635951006 @default.
- W3212454759 cites W2753459921 @default.
- W3212454759 cites W2763161895 @default.
- W3212454759 cites W2768107558 @default.
- W3212454759 cites W2794205914 @default.
- W3212454759 cites W2796582438 @default.
- W3212454759 cites W2802659363 @default.
- W3212454759 cites W2803802743 @default.
- W3212454759 cites W2805354595 @default.
- W3212454759 cites W2887380463 @default.
- W3212454759 cites W2892640821 @default.
- W3212454759 cites W2906250995 @default.
- W3212454759 cites W2910245285 @default.
- W3212454759 cites W2912049913 @default.
- W3212454759 cites W2925446385 @default.
- W3212454759 cites W2938245541 @default.